Terms: = Prostate cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Clinical Outcome
9 results:
1. Salvage Low-Dose-Rate prostate Brachytherapy: clinical outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).
Crook J; Rodgers JP; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Murtha AD; Vigneault E; Helou J; Michalski JM; Roach M; Beyer D; Jani AB; Horwitz EM; Raben A; Pugh S; Sandler H
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1115-1122. PubMed ID: 34740768
[TBL] [Abstract] [Full Text] [Related]
2. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for prostate cancer.
Pollack A; Kwon D; Walker G; Khor LY; Horwitz EM; Buyyounouski MK; Stoyanova R
J Natl Cancer Inst; 2017 Feb; 109(2):1-8. PubMed ID: 28376214
[TBL] [Abstract] [Full Text] [Related]
3. The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.
Kachroo N; Gnanapragasam VJ
J Cancer Res Clin Oncol; 2013 Jan; 139(1):1-24. PubMed ID: 23187933
[TBL] [Abstract] [Full Text] [Related]
4. [clinical study of diethylstilbestrol in hormone refractory prostate cancer].
Wang JW; Zhou LQ; Ji SQ; Song G; Li XS; He ZS
Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(32):2247-9. PubMed ID: 22094088
[TBL] [Abstract] [Full Text] [Related]
5. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy.
Udayakumar T; Shareef MM; Diaz DA; Ahmed MM; Pollack A
Semin Radiat Oncol; 2010 Oct; 20(4):258-66. PubMed ID: 20832018
[TBL] [Abstract] [Full Text] [Related]
6. Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study.
Abdulkader I; Sánchez L; Cameselle-Teijeiro J; Gude F; Chávez JE; López-López R; Forteza J; Fraga M
Oncol Rep; 2005 Dec; 14(6):1527-31. PubMed ID: 16273250
[TBL] [Abstract] [Full Text] [Related]
7. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10.
Chakravarti A; Heydon K; Wu CL; Hammond E; Pollack A; Roach M; Wolkov H; Okunieff P; Cox J; Fontanesi J; Abrams R; Pilepich M; Shipley W;
J Clin Oncol; 2003 Sep; 21(17):3328-34. PubMed ID: 12947069
[TBL] [Abstract] [Full Text] [Related]
8. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(ink4) and p15(ink4B) detected by in situ hybridization in locally advanced prostate cancer.
Heidenreich B; Heidenreich A; Sesterhenn A; Srivastava S; Moul JW; Sesterhenn IA
Eur Urol; 2000 Oct; 38(4):475-82. PubMed ID: 11025389
[TBL] [Abstract] [Full Text] [Related]
9. Tumour suppressor genes in prostate cancer.
MacGrogan D; Bookstein R
Semin Cancer Biol; 1997 Feb; 8(1):11-9. PubMed ID: 9299577
[TBL] [Abstract] [Full Text] [Related]
